XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT AND ENTERPRISE-WIDE INFORMATION | 6 Months Ended
--- | ---
Sep. 27, 2025
Segment Reporting [Abstract] |
SEGMENT AND ENTERPRISE-WIDE INFORMATION | 17. SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer. The Company’s reportable and operating segments are as follows: •Plasma •Blood Center •Hospital The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation. The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources. Selected information by reportable segment is presented below:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Net revenues: |  |  |  |  |  |  |
Plasma | $ | 125,364 |  |  | $ | 138,561 |  |  | $ | 255,261 |  |  | $ | 274,471 |
Blood Center | 56,454 |  |  | 68,528 |  |  | 108,293 |  |  | 134,773 |
Hospital | 145,497 |  |  | 138,422 |  |  | 285,155 |  |  | 272,439 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |
Significant segment expenses and operating performance: |  |  |  |  |  |  |
Plasma |  |  |  |  |  |  |
Cost of goods sold | $ | 53,019 |  |  | $ | 65,726 |  |  | $ | 102,936 |  |  | $ | 131,064 |
Selling, general and administrative | 24,761 |  |  | 25,262 |  |  | 50,959 |  |  | 50,392 |
Research and development | 4,993 |  |  | 3,147 |  |  | 10,490 |  |  | 6,866 |
Plasma operating income | $ | 42,591 |  |  | $ | 44,426 |  |  | $ | 90,876 |  |  | $ | 86,149 |
Blood Center |  |  |  |  |  |  |
Cost of goods sold | $ | 26,948 |  |  | $ | 36,311 |  |  | $ | 52,896 |  |  | $ | 72,491 |
Selling, general and administrative | 13,504 |  |  | 15,202 |  |  | 27,186 |  |  | 30,804 |
Research and development | 1,177 |  |  | 1,213 |  |  | 2,496 |  |  | 2,897 |
Blood Center operating income | $ | 14,825 |  |  | $ | 15,802 |  |  | $ | 25,715 |  |  | $ | 28,581 |
Hospital |  |  |  |  |  |  |
Cost of goods sold | $ | 49,318 |  |  | $ | 47,706 |  |  | $ | 99,534 |  |  | $ | 96,391 |
Selling, general and administrative | 57,966 |  |  | 58,806 |  |  | 120,289 |  |  | 119,996 |
Research and development | 8,352 |  |  | 8,633 |  |  | 17,094 |  |  | 16,256 |
Hospital operating income | $ | 29,861 |  |  | $ | 23,277 |  |  | $ | 48,238 |  |  | $ | 39,796 |
Corporate and unallocated expenses |  |  |  |  |  |  |
Amortization of acquired intangible assets | $ | (13,237) |  |  | $ | (16,003) |  |  | $ | (27,065) |  |  | $ | (33,713) |
Acquisition, integration and divestiture related costs | (1,520) |  |  | (882) |  |  | (4,202) |  |  | (13,205) |
Restructuring and restructuring related costs | (258) |  |  | (6,363) |  |  | (1,582) |  |  | (13,503) |
Digital transformation costs | (5,054) |  |  | (4,858) |  |  | (10,409) |  |  | (11,203) |
Other(1) | (8,717) |  |  | (3,702) |  |  | (9,208) |  |  | 8,551 |
Operating income | 58,491 |  |  | 51,697 |  |  | 112,363 |  |  | 91,453 |
Interest and other expense, net | (7,206) |  |  | (6,993) |  |  | (15,909) |  |  | (36) |
Income before provision for income taxes | $ | 51,285 |  |  | $ | 44,704 |  |  | $ | 96,454 |  |  | $ | 91,417 |
__________ (1) Comprised of litigation-related charges, impairment of intangible assets, and remeasurement of contingent consideration for the three and six months ended September 27, 2025. Comprised of MDR and IVDR costs, litigation-related charges, gains on sale of property, plant and equipment, and impairment of intangible assets for the three and six months ended September 28, 2024. Net revenues by business unit are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Plasma |  |  |  |  |  |  |
Plasma net revenues | $ | 125,364 |  |  | $ | 138,561 |  |  | $ | 255,261 |  |  | $ | 274,471 |
Blood Center |  |  |  |  |  |  |
Apheresis | 56,065 |  |  | 54,332 |  |  | 107,887 |  |  | 103,426 |
Whole Blood | 389 |  |  | 14,196 |  |  | 406 |  |  | 31,347 |
Blood Center net revenues | 56,454 |  |  | 68,528 |  |  | 108,293 |  |  | 134,773 |
Hospital |  |  |  |  |  |  |
Interventional Technologies | 59,073 |  |  | 61,923 |  |  | 117,556 |  |  | 124,967 |
Blood Management Technologies | 86,424 |  |  | 76,499 |  |  | 167,599 |  |  | 147,472 |
Hospital net revenues | 145,497 |  |  | 138,422 |  |  | 285,155 |  |  | 272,439 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Plasma | $ | 12,033 |  |  | $ | 12,032 |  |  | $ | 24,186 |  |  | $ | 23,948 |
Blood Center | 1,849 |  |  | 2,737 |  |  | 3,608 |  |  | 6,190 |
Hospital | 14,373 |  |  | 14,448 |  |  | 29,219 |  |  | 28,215 |
Total depreciation and amortization (excluding impairment charges) | $ | 28,255 |  |  | $ | 29,217 |  |  | $ | 57,013 |  |  | $ | 58,353 |
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
| September 27, 2025 |  | March 29, 2025
| (Dollars in Thousands)
Plasma | $ | 204,258 |  |  | $ | 189,833 |
Blood Center | 39,455 |  |  | 40,337 |
Hospital | 55,304 |  |  | 53,882 |
Total long-lived assets | $ | 299,017 |  |  | $ | 284,052 |
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
| September 27, 2025 |  | March 29, 2025
| (Dollars in Thousands)
United States | $ | 223,664 |  |  | $ | 217,212 |
Japan | 1,195 |  |  | 1,250 |
Europe | 25,292 |  |  | 20,024 |
Rest of Asia | 30,940 |  |  | 28,705 |
Other | 17,926 |  |  | 16,861 |
Total long-lived assets | $ | 299,017 |  |  | $ | 284,052 |
Net revenues by operating regions are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
United States | $ | 240,089 |  |  | $ | 256,061 |  |  | $ | 482,493 |  |  | $ | 504,963 |
Japan | 18,011 |  |  | 16,424 |  |  | 31,659 |  |  | 30,129 |
Europe | 42,965 |  |  | 41,991 |  |  | 83,847 |  |  | 89,216 |
Rest of Asia | 22,567 |  |  | 25,768 |  |  | 44,215 |  |  | 45,551 |
Other | 3,683 |  |  | 5,267 |  |  | 6,495 |  |  | 11,824 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration